AAPS PharmSciTech

, Volume 3, Issue 2, pp 1–8 | Cite as

Pharmaceutical impurities—A mini-review



The control of pharmaceutical impurities is currently a critical issue to the pharmaceutical industry. The International Conference on Harmonization (ICH) has formulated a workable guideline regarding the control of impurities. In this review, a description of different types and origins of impurities in relation to ICH guidelines and, degradation routes, including specific examples, are presented. The article further discusses measures regarding the control of impurities in pharmaceuticals

Key words

Bulk drugs impurities formulation drug stability degradation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    International Conferences on Harmonization, Draft Revised Guidance on Impurities in New Drug Substances. Q3A(R). Federal Register. 2000;65(140):45085–45090.Google Scholar
  2. 2.
    International Conferences on Harmonization, Draft Revised Guidance on Impurities in New Drug Products. Q3B(R). Federal Register. 2000;65(139):44791–44797.Google Scholar
  3. 3.
    International Conferences on Harmonization, Impurities--Guidelines for Residual Solvents. Q3C. Federal Register. 1997;62(247):67377.Google Scholar
  4. 4.
    Ahuja S. Impurities Evaluation of Pharmaceuticals. New York: Marcel Dekker; 1998.Google Scholar
  5. 5.
    Gorog S. Identification and Determination of Impurities in Drugs. Amsterdam: Elsevier Science Publishing Company; 2000.Google Scholar
  6. 6.
    Alsante KM, Hatajik TD, Lohr LL, and Sharp TR. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates. Part 1. American Pharmaceutical Review. 2001; 4(1):70–78.Google Scholar
  7. 7.
    Lohr LL, Sharp TR, Alsante KM, and Hatajik TD. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates. Part II: The roles of NMR and mass spectrometry. American Pharmaceutical Review. Fall issue 2001; Available at: http://www.americanpharmaceuticalreview.com/past_art icles_f.htm.Google Scholar
  8. 8.
    Winger BE, Kemp CAJ. Characterization of pharmaceutical compounds and related substances by using HPLC FTICR-MS and tandem mass spectrometry. American Pharmaceutical Review. Summer issue 2001; Available at: http://www.americanpharma ceuticalreview.com/past_articles_f.htm.Google Scholar
  9. 9.
    Van Krimpen, PC, Van Bennekom WP, Bult A. Penicillins and cephalosporins: physicochemical properties and analysis in pharmaceutical and biological matrices. Pharm Weekbl [Sci]. 1987;9:1–23.Google Scholar
  10. 10.
    Roy J., Mohammad G., and Banu A. Pharmaceutical analysis and stability of locally manufactured ampicillin trihydrate. Indian Drugs. 1993:5(30)5:211–218.Google Scholar
  11. 11.
    British Pharmacopoeia. The British Pharmacopoeia Commission, Vol. 1. The Stationary Office, London, UK; 2001:123, 128.Google Scholar
  12. 12.
    Riley TN. Steric aspects of drug action. US Pharmacist. 1998;23(3):40–51.Google Scholar
  13. 13.
    Roy J, Islam M., Khan AH, Das SC, Akhteruzzaman M, Deb AK, Alam AHM. Diclofenac sodium injection sterilized by autoclave and the occurrence of cyclic reaction producing a small amount of impurity. J Pharm Sci. 2001;(90):541–544.CrossRefGoogle Scholar
  14. 14.
    Walker GJA, Hogerzeil HV, Hillgreen U. Potency of ergometrine in tropical countries. Lancet. 1988;2:393.CrossRefGoogle Scholar
  15. 15.
    Hogerzeil HV, Battersby A, Srdanovic V, and Stjernstrom NE. Stability of essential drugs during shipment to the tropics. BMJ. 1992;304:210–214.Google Scholar
  16. 16.
    Roy J, Bhuiyan K, Faruque A., Sobahan M., Al-Farooque M. Injectable ergometrine: stability and packaging for developing countries. Indian Drugs. 1997;34(11):634–636.Google Scholar
  17. 17.
    Food and Drug Administration for immediate release consumer media: 888-Info.-FDA. May 6, 1998.Google Scholar
  18. 18.
    Hoq MM, Morsheda SB, and Gomes DJ. Development of approapriate preservative system for liquid antacid: bacterial contaminants in antacid samples. Bang J Microbiology. 1991;8(1):5–9.Google Scholar
  19. 19.
    Buhler V. Vademecum for Vitamin Formulation. Stuttgart, Germany: Wiss. Verl-Ges; 1988.Google Scholar
  20. 20.
    Roy J, Mahmud M, Sobhan A, Aktheruzzaman M, Al-Faooque M, Ali E. Marketed vitamin B-complex injectables: stability and mutual interaction. Drug Dev. and Ind Pharm. 1994;20(13):2157–2163.CrossRefGoogle Scholar
  21. 21.
    Connor KA, Amidon GL, Stella VJ. Chemical Stability of Pharmaceuticals-A Handbook for Pharmacists. New York: John Wiley & Sons; 1986.Google Scholar
  22. 22.
    Hoerle SL, Evans KD, and Snider BG. HPLC Determination of Impurities in a 3rd Generation Cephalosporin. Eastern Analytical Symposium. November 16–20, 1992, Somerset, New Jersey.Google Scholar
  23. 23.
    Kumar V, Sunder N, and Potdar A. Critical factors in developing pharmnaceutical formulations- An overview. Part II. Pharmaceutical Technology. 1992;16:86–88.Google Scholar
  24. 24.
    Smith A, Pennefather PM, Kaye SB, and CA Hart CA. Fluoroquinolones—place in ocular therapy. Drugs. 2001;61(6):747–761.CrossRefGoogle Scholar
  25. 25.
    Tobin C. Sunlight, eyes and light-sensitive antibiotics, Southmead Hospital Bristol, University of Bristol. Available at: http://www.irisfund.org.uk/sunlight.htm. Accessed October 27, 2001.Google Scholar
  26. 26.
    Sunderland J, Tobin CM, White LO, MacGowan AP, and Hedges AJ Ofloxacin photodegradation products possess antimicrobial activity. Drugs. 1999; 58(Suppl 2):171–172.CrossRefGoogle Scholar
  27. 27.
    Roy J, Das SC. The effect of sunglight on ciprofloxacin eye drops. In press.Google Scholar
  28. 28.
    Condorelli G., De Guidi G, Giulfrido S, Sortino S, Chilleni R, and Sciuto S. Molecular mechanisms of photosensitization induced by drugs XII. Photochemistry and photosensitization of rufloxacin: An unusual photodegradation path for the antibacterials containing a fluoroquinolone.-like chromophore. Photochemistry & Photobiology. 1999;70(3):280–286.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2002

Authors and Affiliations

  1. 1.Department of BioscienceSalem International UniversitySalem

Personalised recommendations